{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","estimateComment":"Stratified Cox proportional hazard model. Hazard Ratio is Nivolumab + Ipilimumab over Nivolumab.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.85"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.25","upperLimit":"58.71","value":"36.93"},{"groupId":"OG001","lowerLimit":"38.18","upperLimit":"114.37","value":"71.92"},{"groupId":"OG002","lowerLimit":"16.85","upperLimit":"24.61","value":"19.94"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"314"},{"groupId":"OG002","value":"315"}],"units":"Participants"}],"description":"OS was defined as the time between the date of randomization and the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses","id":"OG002","title":"Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization until death (assessed up to approximately 128 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}